Chemical and Pharmaceutical Bulletin
The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 15,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English.
The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Sumio Ohtsuki
Faculty of Life Sciences, Kumamoto University
Read more
28,056 registered articles
(updated on February 05, 2023)
Online ISSN : 1347-5223
Print ISSN : 0009-2363
ISSN-L : 0009-2363
2021 Journal Impact Factor (JIF)
Scopus Pubmed
Featured article
Volume 71 (2023) Issue 2 Pages 120-128
Design, Synthesis, and Biological Evaluation of mTOR-Targeting PROTACs Based on MLN0128 and Pomalidomide Read more
Editor's pick

In this study, several novel PROTACs for the degradation of mTOR were designed based on MLN0128 (mTOR-binding ligand) and pomalidomide (E3 ligase CRBN ligand). PROTAC compounds exhibited mTOR inhibitory activity and suppressed MCF-7 cell proliferation. The representative compound P1 could degrade mTOR and reduce the expression of the mTOR downstream protein p-S6 (Ser240/244) and p-AKT (Ser473). Further studies showed that this compound could inhibit cancer cell growth by inducing autophagy, but it did not affect the cell cycle and apoptosis. This is the first mTOR PROTAC reported and these findings provide new insights in the study of mTOR inhibitors.

Volume 71 (2023) Issue 2 Pages 140-147
Synthesis and Evaluation of 2-Amine-4-oxyphosaniline Pyrimidine Derivatives as EGFR L858R/T790M/C797S Mutant Inhibitors Read more
Volume 71 (2023) Issue 2 Pages 165-174
Quality Evaluation of Humidified Magnesium Oxide Tablet Formulations with Respect to Disintegration Time Prolongation Read more
Editor's pick

Authors conducted a detailed evaluation of the effects of humidification on the quality of five types of commercial magnesium oxide (MgO) tablet formulations by near-infrared spectroscopy, microscopic infrared spectroscopy and thermogravimetry. From these analysis results, it is qualitatively confirmed that the MgO was changed to magnesium hydroxide by humidification. In addition, most tablet formulations tended to prolong disintegration time due to humidification. Thus, in most commercial MgO tablet formulations, it is suggested magnesium hydroxide significantly contributes to prolongation of disintegration time by humidification. The results obtained in this study will provide useful information regarding the handling of MgO tablets in medical sites.

Volume 71 (2023) Issue 2 Pages 175-182
Palladium-Catalyzed C–H Arylation of [1,1′-Biphenyl]-2-ols with Chloroarenes Read more
Editor's pick

Hydroxy-directed, Pd-catalyzed C‒H arylation of [1,1'-biphenyl]-2-ol with haloarenes, developed by Miura et al., is a useful method to synthesize ortho-teraryls. However, only bromo- and iodoarenes were used as arylating agents. In this paper, the authors report that chloroarenes including chloro-containing pharmaceuticals were successfully used as haloarenes for the reactions under optimized reaction conditions. In addition, it was revealed that substituted [1,1'-biphenyl]-2-ols and 2-heteroarylphenols instead of [1,1'-biphenyl]-2-ol were also usable for the reactions. Transformation of the ortho-teraryl product into a triphenylene derivative is also presented.

View all featured articles
View all articles in current issue
Most viewed articles (January 2023)
Share this page
Browse by volume and issue
Announcements from publisher
  • Chem. Pharm. Bull. Vol. 71 No. 2
    Current Topics: Transition Metal Catalysis Research in Pharmaceutical Organic Chemistry
  • Chem. Pharm. Bull. Vol. 71 No. 1
    Current Topics: Applications of Fluorescence Detection in Current Pharmaceutical Research
  • Chem. Pharm. Bull. Vol. 70 No. 12
    Current Topics: Quality Evaluation of Crude Drugs Utilizing Chemometrics